Pfizer&BionTech: Our Vaccine is 91% Effective And Provides Protection Against The South African Strain

Pfizer and BionTech said their COVID-19 vaccine is 91% effective in preventing the disease, according to new trial data that included participants who were vaccinated up to six months ago.

The vaccine was 100% effective in preventing the disease among the participants in the trial in South Africa, where a mutated strain of the Coronavirus known as (B1351) is spreading, despite the fact that the number of participants in it was relatively small and amounted to 800.

While the new efficacy rate of 91.3% is less than the 95% reported during a trial of 44,000 in November, a number of mutated strains of the Coronavirus have spread around the world since then.

Pfizer CEO Albert Bourla said the new findings, which include data from more than 12,000 who were fully vaccinated at least six months ago, pave the way for a request for approval from US regulatory agencies. The vaccine is approved by the US Food and Drug Administration for emergency use.